Sirtex Medical: Biotech Market Spotlight
Friday, 23 October, 2009
Oncology treatment company, Sirtex Medical (ASX:SRX) has continued to perform well, gaining 23c or 3.85% today as of 3pm to $6.20.
This follows a week of strong gains following an announcement on Monday of a 68% increase in operating profit from $3.25 million to $5.47 million for the last financial quarter.
The company also announced a dividend of 2c per share plus a special dividend of 5c per share to be paid in December.
Sirtex Medical, which manufactures SIR-Spheres for the treatment of liver cancer, saw revenues raise from $12.29 million to $16.47 million in the last quarter, a lift of 34%, in spite of a strengthening Australian dollar.
The company's stock has performed well over since the start of the year, with it seeing a 280% lift since January 2.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
